Cardiff Oncology, Inc. (CRDF)
| Market Cap | 162.35M |
| Revenue (ttm) | 610,000 |
| Net Income (ttm) | -40.25M |
| Shares Out | 44.72M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150,922 |
| Open | 3.590 |
| Previous Close | 3.580 |
| Day's Range | 3.525 - 3.750 |
| 52-Week Range | 0.940 - 6.420 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 10.50 (+191.67%) |
| Earnings Date | May 2, 2024 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufact... [Read more]
Financial Performance
In 2023, CRDF's revenue was $488,000, an increase of 26.42% compared to the previous year's $386,000. Losses were -$41.47 million, 7.07% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 191.67% from the latest price.
News
Cardiff Oncology to Present at Upcoming Investor Conferences in May
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancer...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated m...
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m.
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vasculariz...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite -
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients -
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting -
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m.
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
- Findings from the Phase 1b portion of company's Phase 1b/2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care - - ...
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
SAN DIEGO , Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
- Advance to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA - - Expanded relationship with Pfizer, w...
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
- Management will hold a conference call on Thursday, November 2 at 4:30 p.m. ET/1:30 p.m.
Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks
Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% (vs.
Cardiff Oncology to Present at Upcoming Investor Conferences in September
SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
- New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 - - Advance to first-line mCRC follows stro...
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA - - First-line mCRC represents substantial increase in patient impact...
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , July 24, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...
Cardiff Oncology to Present at the Jefferies Healthcare Conference
SAN DIEGO , June 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop nov...
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (...
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
SAN DIEGO , March 28, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop n...
Cardiff Oncology Formally Introduces Scientific Advisory Board
- SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will continue to provide insight and guidance on the ...
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective response rate, durability and progression-f...